MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Palliative Care in Advanced Parkinson’s Disease: Descriptive Analysis and Symptom Impact

C. Armengol-García, J. Hartmann-Nava, D. Martínez-Ramírez (Monterrey, Mexico)

Meeting: 2024 International Congress

Abstract Number: 866

Keywords: Interventions, Parkinson’s, Scales

Category: Parkinson’s Disease: Pharmacology and Therapy

Objective: These preliminary study aims to describe the primary clinical features of Parkinson’s disease patients requiring palliative care, as assessed by the Edmonton Symptom Assessment System for Parkinson’s Disease (ESAS-PD), and to identify the impact palliative care has on improvement of symptoms.

Background: In the later stages of Parkinson’s disease, improving quality of life requires a holistic approach that extends beyond traditional pharmaceutical treatments. Patients benefit from a comprehensive care plan that integrates input from various specialists, treating them as part of a collaborative team effort. The involvement of a palliative care specialist is crucial as they address symptoms unrelated to the motor aspect of the disease, focusing on overall well-being and facilitating improved coping mechanisms for patients. Their expertise ensures personalized support.

Method: This is a case series of patients diagnosed with Parkinson’s disease for more than 10 years, identified by the principal investigator as requiring palliative care, they were referred to a consultation with a palliative care specialist. During the initial meeting, the ESAS-PD was administered. Additionally, assessments for other complications such as immobility, insomnia and falls were conducted, alongside a review of their current medication regimen.

Results: In these preliminary results, we evaluated eight patients, comprising five males and three females, with a mean age of 79 (±4) years. The mean score on the ESAS-PD was 55 (±14). Among the clinical manifestations reported by patients, fatigue had a mean score of 8 (6-9), anxiety had a mean score of 6 (4-8), and depression had a mean 6 score of (1-10), indicating these as the most prevalent symptoms. Insomnia, immobility, and falls were identified as major problems aside from those related to the ESAS-PD questionnaire, in the daily lives of half of the patients. Additionally, the mean daily levodopa dosage was 600 (±213) mg.

Conclusion: Symptoms such as anxiety, depression, and fatigue seem to emerge as pivotal factors contributing to a diminished quality of life among patients in the advanced stages of Parkinson’s disease. Addressing these symptoms should be a focal point within the holistic treatment approach for Parkinson’s disease. Further exploration is warranted to investigate the role of palliative care in alleviating these symptoms and enhancing the overall quality of life.

To cite this abstract in AMA style:

C. Armengol-García, J. Hartmann-Nava, D. Martínez-Ramírez. Palliative Care in Advanced Parkinson’s Disease: Descriptive Analysis and Symptom Impact [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/palliative-care-in-advanced-parkinsons-disease-descriptive-analysis-and-symptom-impact/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/palliative-care-in-advanced-parkinsons-disease-descriptive-analysis-and-symptom-impact/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley